Handok

Handok Financial Leverage

The Financial Leverage (Equity Multiplier) of Handok (002390.KS) as of Oct 22, 2026 is 2.86. In the previous year, Financial Leverage (Equity Multiplier) was 2.75 — a change of 4.14% (higher).

Financial Leverage

2.86

YoY

4.14%

Last updated:

Financial Leverage (Equity Multiplier) of Handok is 2025 2.86 . Financial Leverage (Equity Multiplier) of Handok was 2024 2.75 . It decreases by 4.14% higher compared to the previous year.

The Handok Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2018
2.12 KRW
Jan 1, 2019
2.20 KRW
Jan 1, 2020
2.15 KRW
Jan 1, 2021
2.19 KRW
Jan 1, 2022
2.29 KRW
Jan 1, 2023
2.33 KRW
Jan 1, 2024
2.75 KRW
Jan 1, 2025
2.86 KRW
The Handok Financial Leverage history
YEARFinancial LeverageYoY
2.86+4.14%
2.75+17.65%
2.33+1.73%
2.29+4.65%
2.19+2.04%
2.15-2.25%
2.20+3.49%
2.12-5.59%
2.25+1.42%
2.22+24.75%
1.78+6.14%
1.67—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Handok Stock analysis

What does Handok do? Handok, Inc. generates revenue through the manufacture and sale of pharmaceutical products including Amaryl for diabetes, Tritace for hypertension and cardiovascular diseases, Teveten and Triapin for hypertension, Munobal for hypertension and stenocardia, Ketas for cerebral circulation issues, and Lasix for hypertension and edema. The company also sells over-the-counter pharmaceuticals, healthcare products, medical devices, diagnostic reagents, and vaccines. Additionally, Handok, Inc. earns income from real estate rental services. Its products target healthcare providers, hospitals, and pharmacies as key buyers within the pharmaceutical and healthcare sectors. The firm's product portfolio includes branded medications such as Amaryl, Tritace, Teveten, Triapin, Munobal, Ketas, and Lasix, which are distributed to medical professionals and retail pharmacies. Over-the-counter products and healthcare items are sold directly to consumers through retail channels. Medical devices and diagnostic reagents are supplied to healthcare facilities and laboratories. Vaccines are distributed to public health institutions and clinics. Handok, Inc. serves multiple market segments including diabetes management, cardiovascular care, hypertension treatment, and neurological health through its diverse product range. The company's real estate rental business supports its financial operations by providing steady income streams from leased properties. Key buyers include healthcare providers, pharmacies, hospitals, and public health institutions that purchase its branded pharmaceuticals and medical solutions. Handok is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Handok stock

Financial Leverage (Equity Multiplier) of Handok is 2.86 in 2025.

Financial Leverage (Equity Multiplier) of Handok changed from 2.75 to 2.86, representing a 4.14% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Handok since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Handok with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Handok

All Key Metrics — Handok